Parallel Advisors, LLC Exact Sciences Corp Transaction History

Parallel Advisors, LLC

$4.18 Billion
Q3 2024

A detailed history of Parallel Advisors, LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Parallel Advisors, LLC holds 773 shares of EXAS stock, worth $39,368. This represents 0.0% of its overall portfolio holdings.

Number of Shares

773

Previous 448 72.54%

Holding current value

$39,368

Previous $18,000 188.89%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$42.43 - $70.83 $13,789 - $23,019	325 Added 72.54%	773 $52,000
Q2 2024 Aug 08, 2024	SELL	$41.33 - $74.26 $3,306 - $5,940	-80 Reduced 15.15%	448 $18,000
Q1 2024 May 06, 2024	SELL	$56.27 - $73.77 $5,964 - $7,819	-106 Reduced 16.72%	528 $36,000
Q4 2023 Feb 09, 2024	BUY	$59.06 - $75.72 $708 - $908	12 Added 1.93%	634 $46,000
Q3 2023 May 20, 2024	SELL	$65.94 - $99.04 $527 - $792	-8 Reduced 1.27%	622 $42,000
Q3 2023 Nov 13, 2023	SELL	$65.94 - $99.04 $527 - $792	-8 Reduced 1.27%	622 $42,000
Q2 2023 May 20, 2024	BUY	$62.68 - $95.05 $564 - $855	9 Added 1.45%	630 $59,000
Q2 2023 Aug 04, 2023	BUY	$62.68 - $95.05 $564 - $855	9 Added 1.45%	630 $59,000
Q1 2023 May 20, 2024	BUY	$47.19 - $70.77 $4,388 - $6,581	93 Added 17.61%	621 $42,000
Q1 2023 Apr 25, 2023	BUY	$47.19 - $70.77 $1,368 - $2,052	29 Added 4.9%	621 $42,000
Q4 2022 Feb 03, 2023	BUY	$30.35 - $53.15 $2,670 - $4,677	88 Added 17.46%	592 $29,000
Q3 2022 Nov 10, 2022	BUY	$31.97 - $49.37 $1,534 - $2,369	48 Added 10.53%	504 $16,000
Q2 2022 Aug 01, 2022	BUY	$35.61 - $76.23 $2,029 - $4,345	57 Added 14.29%	456 $18,000
Q1 2022 Apr 28, 2022	SELL	$57.56 - $82.54 $24,405 - $34,996	-424 Reduced 51.52%	399 $28,000
Q4 2021 Jan 20, 2022	SELL	$72.5 - $100.68 $22,692 - $31,512	-313 Reduced 27.55%	823 $64,000
Q3 2021 Nov 02, 2021	BUY	$90.24 - $124.05 $43,224 - $59,419	479 Added 72.91%	1,136 $108,000
Q2 2021 Aug 06, 2021	BUY	$93.66 - $139.27 $6,649 - $9,888	71 Added 12.12%	657 $82,000
Q1 2021 Apr 23, 2021	BUY	$116.57 - $155.01 $2,797 - $3,720	24 Added 4.27%	586 $77,000
Q4 2020 Feb 02, 2021	BUY	$99.61 - $142.12 $2,789 - $3,979	28 Added 5.24%	562 $74,000
Q3 2020 Oct 27, 2020	SELL	$72.92 - $102.01 $26,761 - $37,437	-367 Reduced 40.73%	534 $54,000
Q2 2020 Jul 16, 2020	BUY	$55.75 - $92.75 $5,965 - $9,924	107 Added 13.48%	901 $78,000
Q1 2020 Apr 27, 2020	SELL	$37.9 - $104.44 $5,647 - $15,561	-149 Reduced 15.8%	794 $46,000
Q4 2019 Jan 30, 2020	BUY	$77.66 - $99.74 $11,260 - $14,462	145 Added 18.17%	943 $87,000
Q3 2019 Nov 01, 2019	BUY	$90.37 - $122.49 $2,439 - $3,307	27 Added 3.5%	798 $72,000
Q2 2019 Aug 05, 2019	BUY	$89.51 - $118.04 $26,853 - $35,412	300 Added 63.69%	771 $91,000
Q1 2019 May 01, 2019	BUY	$61.98 - $96.5 $19,337 - $30,108	312 Added 196.23%	471 $41,000
Q4 2018 Feb 05, 2019	BUY	$56.04 - $82.66 $7,453 - $10,993	133 Added 511.54%	159 $10,000
Q2 2018 Jul 30, 2018	BUY	$37.84 - $69.96 $983 - $1,818	26 New	26 $1,000
Q3 2017 Nov 14, 2017	SELL	$37.05 - $47.12 $185 - $235	-5 Closed	0 $0
Q2 2017 Aug 07, 2017	BUY	N/A	5	5 $0

Others Institutions Holding EXAS

# of Institutions

666

Shares Held

162M

Call Options Held

2.32M

Put Options Held

1.68M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $9.01B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.

Account

Parallel Advisors, LLC Exact Sciences Corp Transaction History